Andreas Wallnöfer has over 25 years of experience in the pharmaceutical and biotech industry, including 12 years as a member of the F. Hoffmann-La Roche Pharma R&D Executive Leadership team and nearly a decade as a board member in several biotech companies. He has been a Partner at the Swiss venture capital firm BioMedPartners and later at Jeito Capital, a leading European investment company based in Paris.

An accomplished investor, board member and operator, Andreas has played a pivotal role in developing successfully many innovative companies. He has contributed to several successful exits, including the recent acquisition of EyeBio by MSD, a deal valued in total at US $3 billion, achieved only 3 years after the company’s inception.

Prior to his career in venture capital, he was Head of Cardiovascular and Metabolism (CVM) R&D at Roche and a member of the Roche/Genentech Portfolio Committee. Andreas was part of several successful product developments and market introductions. Before the integration of Genentech (now a wholly owned member of The Roche Group), Andreas was Global Head of Clinical Research and Exploratory Development and led the R&D organization at multiple sites in Europe, the U.S., and Asia. He had a key role in the integration of the Roche and Genentech development organizations and subsequently led Roche’s Early Development Department.

Andreas is currently involved in several biotech companies: Chair of Nuevocor (cardiology. Singapore/Paris) and independent board member at Nuemirna (neurology, Copenhagen) and Immios (immunology, Oss), as well as SAB member in several other companies. He also advises Singapore Government (ASTAR and EDB) in the development of the Singapore biotech ecosystem and is member of the ASTAR PRC Governing board.      

Andreas holds a Ph.D. in Pharmacology from the University of Basel, degrees in Pharmaceutical Medicine, and was trained as a Clinical Research fellow at the Centre of Human Drug Research at the University Hospital of Leiden, Netherlands. He also holds an Executive M.B.A. from IMD Lausanne.